27.75

2.78% 0.75

After Hours: 27.75

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $27.75, with a volume of 857.17K. It is up +2.78% in the last 24 hours and up +21.13% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$27.00

Open:

$27.19

24h Volume:

857.17K

Relative Volume:

0.95

Market Cap:

$1.64B

Revenue:

$13.05M

Net Income/Loss:

$-60.54M

P/E Ratio:

-23.92

EPS:

-1.16

Net Cash Flow:

$-37.82M

1W Performance:

+8.36%

1M Performance:

+21.13%

6M Performance:

-31.85%

1Y Performance:

-36.80%

1-Day Range:

$27.19

$27.85

1-Week Range:

$24.80

$27.85

52-Week Range:

$22.48

$71.71

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (657)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	27.75	1.52B	13.05M	-60.54M	-37.82M	-1.16
VRTX Vertex Pharmaceuticals Inc	463.27	123.14B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	550.00	60.43B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	324.69	42.07B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	572.71	34.47B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	290.35	27.42B	3.81B	-644.79M	-669.77M	-6.24

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-11-25	Initiated	Raymond James	Outperform
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Jul 17, 2025

Janux Therapeutics to Showcase New Preclinical Programs at Virtual R&D Day - AInvest

Jul 17, 2025

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - Business Wire

Jul 17, 2025

September 19th Options Now Available For Janux Therapeutics (JANX) - Nasdaq

Jul 17, 2025

Jul 15, 2025

How Janux Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser

Jul 15, 2025

Why Janux Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser

Jul 15, 2025

What makes Janux Therapeutics Inc. stock price move sharplyProfessional Stock Screener - Newser

Jul 15, 2025

Jul 13, 2025

Raymond James Financial Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World

Jul 13, 2025

Argus Initiates Coverage on CoreWeave (NASDAQ:CRWV) - Defense World

Jul 13, 2025

Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World

Jul 13, 2025

Jul 12, 2025

Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Jul 12, 2025

Raymond James initiates Janux Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada

Jul 12, 2025

Jul 11, 2025

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 11, 2025

Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target - MarketScreener

Jul 11, 2025

Janux Therapeutics initiated with an Outperform at Raymond James - TipRanks

Jul 11, 2025

Jul 09, 2025

KBC Group NV Invests $66,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Jul 09, 2025

Jul 06, 2025

(JANX) On The My Stocks Page - news.stocktradersdaily.com

Jul 06, 2025

Jul 04, 2025

Janux Therapeutics Insiders Sell US$5.6m Of Stock, Possibly Signalling Caution - simplywall.st

Jul 04, 2025

Jul 03, 2025

Top Defense Stocks To Follow Now – July 1st - Defense World

Jul 03, 2025

Jul 01, 2025

2025's 10 Worst-Performing Stocks | Investing - US News Money

Jul 01, 2025

Jun 27, 2025

GAMMA Investing LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Jun 27, 2025

Jun 25, 2025

Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail

Jun 25, 2025

Jun 24, 2025

JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - Yahoo Finance

Jun 24, 2025

Jun 20, 2025

SG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Jun 20, 2025

Jun 18, 2025

Janux Therapeutics Becomes Oversold (JANX) - Nasdaq

Jun 18, 2025

Jun 17, 2025

Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX

Jun 17, 2025